RPRX Royalty Pharma plc

67.72USD-1.38%Mkt Cap: 38.94B USDP/E: 44.26

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed th…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap38.94B USD
Enterprise Value41.58B USD
Revenue (TTM)2.62B USD
Gross Profit2.43B USD
Net Income (TTM)770.95M USD
Revenue/Share5.96 USD
Last Price67.72 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)44.26
P/E (Forward)11.49
PEG2.08
EV/EBITDA24.59
EV/Revenue15.89
P/S14.88
P/B4.42
EPS (TTM)1.53 USD
EPS (Forward)5.91 USD
52W Range
37.3192% of range70.37
52W High70.37 USD
52W Low37.31 USD
Profitability
Gross Margin95.82%
Oper. Margin64.41%
EBITDA Margin64.60%
Profit Margin32.42%
ROE11.90%
ROA3.93%
ROIC9.08%
ROCE8.21%
Growth
Revenue Growth13.30%
Earnings Growth-50.80%
Cash Flow & Leverage
Operating CF2.49B USD
CapEx (TTM)—
FCF Margin-17.21%
FCF Yield-1.16%
Net Debt8.04B USD
Net Debt/EBITDA4.76
Net Debt/FCF—
Balance Sheet
Debt/Equity1.38
Current Ratio1.29
Quick Ratio1.29
Book Value/Sh15.34 USD
Cash/Share1.22 USD
Dividends
Fwd Div Rate0.94 USD
Trail. Div Rate0.93 USD
Div. Yield1.37%
5Y Avg Yield2.16%
Payout Ratio60.46%
Ex-Div DateNov 13, 2026
Pay DateDec 10, 2026
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)73.50 USD
Upside (mean)+8.5%
Target Range66.00 USD – 80.00 USD
66.00+8.5% to mean80.00
# Analysts8
Ownership
Shares Out.445.27M
Float417.10M
Insiders6.50%
Institutions89.92%
Short Interest
Short Ratio4.0d
Short % Float2.98%
Short % Out.2.94%
Shares Short13.08M
Short (prev mo.)12.89M
Technical
SMA 5061.61 (+9.9%)
SMA 20054.76 (+23.7%)
Beta0.36
S&P 52W Chg12.08%
Avg Vol (30d)3.31M
Avg Vol (10d)3.72M
Technical Indicators
RSI (14)60.1
MACD1.9262
MACD Signal2.1744
MACD Hist.-0.2482
BB Upper70.87 USD
BB Middle67.36 USD
BB Lower63.86 USD
BB Width10.40%
ATR (14)1.515 USD
Vol Ratio (20d)0.82x

About Royalty Pharma (NASDAQ: RPRX)

›

Royalty Pharma (NASDAQ: RPRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 100 employees.

The shares were at 67.72 USD on 19 November 2026, up 70.1% over 52 weeks. Its 52-week range is 37.31 USD to 70.37 USD: the price is 3.8% below the high and 81.5% above the low.

At a market capitalisation of 38.94B USD, it trades at 44.3 times trailing earnings and 11.5 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 32% for RPRX. It pays a dividend yielding 1.37% (it pays out 60% of its earnings), against a median of 0.51% among the dividend payers in that peer group.

Royalty Pharma reports return on equity of 11.9%, an operating margin of 64.4% and revenue up 13.3% year over year.

Its debt exceeds its cash by 8.04B USD, a debt-to-equity ratio of 1.38. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 73.50 USD is 8.5% above the current price. The next earnings report is expected on 10 February 2027.